Stem cells with fused gene expression of cytosine deaminase and interferon-β migrate to human gastric cancer cells and result in synergistic growth inhibition for potential therapeutic use

International Journal of Oncology

Volumn 40, Issue 4, 2012, Pages 1097-1104

  Kim, Kyoung Yoon ^a   Yi, Bo Rim ^a   Lee, Hye Rim ^a   Kang, Nam Hee ^a   Jeung, Eui Bae ^a   Kim, Seung U ^b,c   Choi, Kyung Chul ^a  

^a Chungbuk National University   (South Korea)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c Chung Ang University College of Medicine   (South Korea)

Author keywords

Cytosine deaminase; Gastric cancer; Interferon ; Therapeutic stem cells

Indexed keywords

BETA INTERFERON; CHEMOKINE RECEPTOR CXCR4; CYTOSINE DEAMINASE; FLUOROURACIL; STEM CELL FACTOR; STEM CELL FACTOR RECEPTOR; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; CELL VIABILITY; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFECT; ESCHERICHIA COLI; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; NEURAL STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; STOMACH CARCINOMA;

ADENOCARCINOMA; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CYTOSINE DEAMINASE; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; HUMANS; INTERFERON-BETA; STEM CELLS; STOMACH NEOPLASMS; TRANSFECTION;

EID: 84863338420     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1288     Document Type: Article

References (50)

1. Isik M, Caner S, Metin Seker M, et al: Gastric adenocarcinoma under the age of 40; more metastatic, less differentiated. J BUON 16: 253-256, 2011.
2. Blum M, Suzuki A and Ajani JA: A comprehensive review of S-1 in the treatment of advanced gastric adenocarcinoma. Future Oncol 7: 715-726, 2011.
3. Fidan E, Fidan S, Yildiz B, et al: Bolus fluorouracil induced syncope and pulseless ventricular tachycardia: a case report. Hippokratia 15: 93-95, 2011.
4. Longley DB, Harkin DP and Johnston PG: 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003.
5. Luo XR, Li JS, Niu Y and Miao L: Targeted killing effects of double CD and TK suicide genes controlled by survivin promoter on gastric cancer cell. Mol Biol Rep 38: 1201-1207, 2011.
6. Anderson LM, Krotz S, Weitzman SA and Thimmapaya B: Breast cancer-specific expression of the Candida albicans cytosine deaminase gene using a transcriptional targeting approach. Cancer Gene Ther 7: 845-852, 2000. (Pubitemid 30437284)
7. Joo KM, Park IH, Shin JY, et al: Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. Mol Ther 17: 570-575, 2009.
8. Studeny M, Marini FC, Champlin RE, Zompetta C, Fidler IJ and Andreeff M: Bone marrow-derived mesenchymal stem cells as vehicles for interferon-β delivery into tumors. Cancer Res 62: 3603-3608, 2002.
9. Zhang JF, Wei F, Wang HP, et al: Potent anti-tumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. J Exp Clin Cancer Res 29: 52, 2010.
10. Aboody KS, Brown A, Rainov NG, et al: Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proc Natl Acad Sci USA 97: 12846-12851, 2000.
11. Aboody KS, Bush RA, Garcia E, et al: Development of a tumor-selective approach to treat metastatic cancer. PLoS One 1: e23, 2006.
12. Kim SK, Kim SU, Park IH, et al: Human neural stem cells target experimental intracranial medulloblastoma and deliver a therapeutic gene leading to tumor regression. Clin Cancer Res 12: 5550-5556, 2006. (Pubitemid 44497273)
13. Kim KY, Kim SU, Leung PC, Jeung EB and Choi KC: Influence of the prodrugs 5-fluorocytosine and CPT-11 on ovarian cancer cells using genetically engineered stem cells: tumor-tropic potential and inhibition of ovarian cancer cell growth. Cancer Sci 101: 955-962, 2010.
14. Kim SU: Human neural stem cells genetically modified for brain repair in neurological disorders. Neuropathology 24: 159-171, 2004.
15. Kim SU, Nakagawa E, Hatori K, Nagai A, Lee MA and Bang JH: Production of immortalized human neural crest stem cells. Methods Mol Biol 198: 55-65, 2002.
16. Evoy D, Hirschowitz EA, Naama HA, et al: In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J Surg Res 69: 226-231, 1997. (Pubitemid 27265855)
17. Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ and Crystal RG: In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther 6: 1055-1063, 1995.
18. Kanai F, Lan KH, Shiratori Y, et al: In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus- mediated transfer of cytosine deaminase gene. Cancer Res 57: 461-465, 1997. (Pubitemid 27081664)
19. Lan KH, Kanai F, Shiratori Y, et al: Tumor-specific gene expression in carcinoembryonic antigen - producing gastric cancer cells using adenovirus vectors. Gastroenterology 111: 1241-1251, 1996.
20. Li Z, Shanmugam N, Katayose D, et al: Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther 4: 113-117, 1997. (Pubitemid 127667106)
21. Austin EA and Huber BE: A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase. Mol Pharmacol 43: 380-387, 1993. (Pubitemid 23081994)
22. Mullen CA, Kilstrup M and Blaese RM: Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: a negative selection system. Proc Natl Acad Sci USA 89: 33-37, 1992.
23. Etienne MC, Cheradame S, Fischel JL, et al: Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 13: 1663-1670, 1995.
24. Pinedo HM and Peters GF: Fluorouracil: biochemistry and pharmacology. J Clin Oncol 6: 1653-1664, 1988.
25. Chung-Faye GA, Chen MJ, Green NK, et al: In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther 8: 1547-1554, 2001. (Pubitemid 33061893)
26. Crystal RG, Hirschowitz E, Lieberman M, et al: Phase I study of direct administration of a replication deficient adenovirus vector containing the E. coli cytosine deaminase gene to meta-static colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther 8: 985-1001, 1997. (Pubitemid 27270161)
27. Freytag SO, Khil M, Stricker H, et al: Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 62: 4968-4976, 2002.
28. Dong Z, Greene G, Pettaway C, et al: Suppression of angio-genesis, tumorigenicity, and metastasis by human prostate cancer cells engineered to produce interferon-β. Cancer Res 59: 872-879, 1999.
29. Rossiello F, De Cicco Nardone F and Dell'Acqua S: Interferon-β increases the sensitivity of endometrial cancer cells to cell-mediated cytotoxicity. Gynecol Oncol 54: 130-136, 1994.
30. Yi BR, Hwang KA, Kang NH, Kim SU, Jeung EB and Choi KC: Antitumor therapeutic effects of cytosine deaminase and interferon-β against endometrial cancer cells using genetically engineered stem cells in vitro. Anticancer Res 31: 2853-2862, 2011.
31. Yi BR, O SN, Kang NH, et al: Genetically engineered stem cells expressing cytosine deaminase and interferon-β migrate to human lung cancer cells and have potentially therapeutic anti-tumor effects. Int J Oncol 39: 833-839, 2011.
32. Schmidt NO, Przylecki W, Yang W, et al: Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. Neoplasia 7: 623-629, 2005. (Pubitemid 40967763)
33. Sun L, Lee J and Fine HA: Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J Clin Invest 113: 1364-1374, 2004. (Pubitemid 39069935)
34. Ehtesham M, Yuan X, Kabos P, et al: Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4. Neoplasia 6: 287-293, 2004. (Pubitemid 38657085)
35. Jeong SW, Chu K, Jung KH, Kim SU, Kim M and Roh JK: Human neural stem cell transplantation promotes functional recovery in rats with experimental intracerebral hemorrhage. Stroke 34: 2258-2263, 2003. (Pubitemid 37099846)
36. Kim SU, Park IH, Kim TH, et al: Brain transplantation of human neural stem cells transduced with tyrosine hydroxylase and GTP cyclohydrolase 1 provides functional improvement in animal models of Parkinson disease. Neuropathology 26: 129-140, 2006.
37. Meng XL, Shen JS, Ohashi T, Maeda H, Kim SU and Eto Y: Brain transplantation of genetically engineered human neural stem cells globally corrects brain lesions in the mucopolysaccharidosis type VII mouse. J Neurosci Res 74: 266-277, 2003. (Pubitemid 37193713)
38. Rosser AE, Zietlow R and Dunnett SB: Stem cell transplantation for neurodegenerative diseases. Curr Opin Neurol 20: 688-692, 2007. (Pubitemid 350085011)
39. Ryu JK, Kim J, Cho SJ, et al: Proactive transplantation of human neural stem cells prevents degeneration of striatal neurons in a rat model of Huntington disease. Neurobiol Dis 16: 68-77, 2004. (Pubitemid 38569797)
40. Lee ST, Chu K, Park JE, et al: Intravenous administration of human neural stem cells induces functional recovery in Huntington's disease rat model. Neurosci Res 52: 243-249, 2005. (Pubitemid 40775763)
41. Lee DH, Ahn Y, Kim SU, et al: Targeting rat brainstem glioma using human neural stem cells and human mesenchymal stem cells. Clin Cancer Res 15: 4925-4934, 2009.
42. Boucher PD, Im MM, Freytag SO and Shewach DS: A novel mechanism of synergistic cytotoxicity with 5-fluorocytosine and ganciclovir in double suicide gene therapy. Cancer Res 66: 3230-3237, 2006.
43. Hartmann KU and Heidelberger C: Studies on fluorinated pyrimidines. XIII. Inhibition of thymidylate synthetase. J Biol Chem 236: 3006-3013, 1961.
44. Wei J, Wahl J, Knauss H, et al: Cytosine deaminase/5-fluorocytosine gene therapy and Apo2L/TRAIL cooperate to kill TRAIL-resistant tumor cells. Cancer Gene Ther 14: 640-651, 2007. (Pubitemid 46912036)
45. Huber BE, Austin EA, Richards CA, Davis ST and Good SS: Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA 91: 8302-8306, 1994.
46. Saukkonen K and Hemminki A: Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 4: 683-696, 2004. (Pubitemid 38667814)
47. Tubiana M: Tumor cell proliferation kinetics and tumor growth rate. Acta Oncol 28: 113-121, 1989.
48. Beppu K, Jaboine J, Merchant MS, Mackall CL and Thiele CJ: Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J Natl Cancer Inst 96: 46-55, 2004. (Pubitemid 38180959)
49. Sun L, Hui AM, Su Q, et al: Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 9: 287-300, 2006.
50. Nakamizo A, Marini F, Amano T, et al: Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65: 3307-3318, 2005. (Pubitemid 40524615)